Zalicus in The New York Times (Friday, September 27, 2013)
News about Zalicus Inc., including commentary and archival articles published in The New York Times.
Zalicus Inc. (Zalicus) is a biopharmaceutical company that discovers and developsl treatments for patients suffering from pain and immuno-inflammatory diseases. The Company has a portfolio of clinical-stage product candidates targeting pain and immuno-inflammatory diseases and have entered into multiple revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. It focuses on the discovery and development of selective ion channel modulators and its combination high throughput screening technology (cHTSTM) to discover new product candidates for its portfolio or for its collaborators in the areas of pain, inflammation, oncology and infectious disease.
Third Floor, 245 First St. CAMBRIDGE MA 02142
Phone: +1 (617) 301-7000
Fax: +1 (617) 301-7010